From Our 2009 Archives
Treating Childhood Leukemia With Fewer Side Effects
Latest Cancer News
THURSDAY, Sept. 10 (HealthDay News) -- Adding the corticosteroid dexamethasone to the treatment regimen of children with acute lymphoblastic leukemia improves survival rates and reduces the incidence of the cancer recurring, a new Dutch study shows.
Acute lymphoblastic leukemia (ALL), a cancer of the blood, is the most common childhood cancer and is highly treatable, according to background information in the study.
The study found that a dexamethasone-based treatment can improve the cancer cure rate and reduce the risk of relapse without radiation and routinely used chemotherapy drugs. The findings were published online Sept. 9 The Lancet Oncology.
Dexamethasone is sold under the brand name Decadron.
The study involved 859 youths, aged 1 to 18, with ALL. About 30% of them were considered to be at high risk for recurrence.
Participants not at high risk were given a basic three-drug induction (dexamethasone, vincristine and L-asparaginase) and medium-dose methotrexate. High-risk youths were given a four-drug induction (the same three drugs as the others got plus four doses of daunorubicin), consolidation with methotrexate and two intensification courses before maintenance, which was 109 weeks for all participants.
Triple intrathecal chemo was given 13 times in those not at high risk, 15 times in high-risk youths and 17 times in those with initial central nervous system involvement. No one was given cranial radiation.
Five-year, cancer-free survival for the high-risk group was 72%, the study found. Those not at high risk had an 84% survival rate. About 70% of all people newly diagnosed are not at high risk, according to the researchers.
The results for those not at high risk "were achieved with high cumulative doses of dexamethasone and vincristine, but without the use of anthracyclines, etoposide, cyclophosphamide or cranial irradiation, therefore minimizing the risk of side effects," they said in a news release from the journal. The survival rate for the high-risk group also was described as favorable.
-- Jennifer Thomas
SOURCE: The Lancet Oncology, news release, Sept. 9, 2009
Copyright © 2009 ScoutNews, LLC. All rights reserved.